Related Experiment Videos
New therapeutics that modulate chemokine networks
Matthias K Schwarz1, Timothy N C Wells
1Serono Pharmaceutical Research Institute, 14 Chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland.
Nature Reviews. Drug Discovery
|July 18, 2002
Summary
Chemokine receptor antagonists offer targeted control over immune cell recruitment and activation. This research anticipates the development of novel therapies for various diseases within years.
Area of Science:
- Immunology
- Pharmacology
Background:
- Chemokines are small cytokines regulating critical biological and pathological processes, including immune surveillance, inflammation, viral infection, and cancer.
- Numerous chemokine receptors exist, presenting opportunities for targeted therapeutic interventions.
- Chemokine receptors, being G-protein-coupled receptors, are prime targets for pharmaceutical development.
Purpose of the Study:
- To explore the potential of selective chemokine receptor antagonism.
- To investigate the development of small-molecule antagonists for chemokine receptors.
- To assess the therapeutic prospects of targeting chemokine pathways.
Main Methods:
- Review of existing literature on chemokine receptor antagonists.
- Analysis of in vitro studies demonstrating antagonist efficacy.
- Examination of animal models of disease utilizing chemokine receptor antagonism.
Main Results:
- Successful in vitro and in vivo demonstrations of chemokine receptor antagonist activity.
- Evidence supporting the feasibility of developing selective antagonists.
- Identification of potential therapeutic applications in various diseases.
Conclusions:
- Chemokine receptor antagonism holds significant promise for therapeutic development.
- Small-molecule antagonists for chemokine receptors are nearing clinical applicability.
- Targeting chemokine pathways could lead to novel treatments for inflammatory and other diseases in the near future.